Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
23 2월 2023 - 10:00PM
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research, and development of innovative treatments for Central
Nervous System (CNS) disorders, today announced that Lawrence
Steinman, Pasithea’s Chairman and National Academy of Sciences
Professor, will deliver the Dr. Kenneth P. Johnson lecture at the
Americas Committee for Treatment and Research in Multiple Sclerosis
(ACTRIMS) on February 23 in San Diego, California.
The ACTRIMS Forum is a translational science
meeting focusing on scientific discoveries made in multiple
sclerosis (MS) to advance the understanding of research and
clinical care of patients with MS. The lecture allows attendees an
opportunity to hear from a prestigious researcher selected for
their contributions to multiple sclerosis. Prof. Steinman’s
research on the link between Epstein-Barr virus and multiple
sclerosis was a runner-up for Science Magazine’s 2022 Breakthrough
of the Year.
About PAS-002
The Company’s PAS-002 discovery program aims to
develop a proprietary engineered DNA plasmid vaccine to tolerize
the immune system to GlialCAM for the treatment of multiple
sclerosis. GlialCAM, a CNS protein, found in the brain’s white
matter is attacked in MS. GlialCAM shares a component of its
structure that mimics an identical component of Epstein-Barr virus
nuclear antigen 1 (EBNA-1), which plays a critical role in
triggering MS.
About Multiple Sclerosis
Multiple sclerosis (“MS”) is a chronic and
potentially disabling autoimmune disease, and the most common
neurodegenerative disease of the central nervous system in young
adults. The pathological hallmark of MS is the formation of
demyelinating lesions in the brain and spinal cord, with the immune
system attacking the myelin sheath that normally protects nerve
fibers in the brain, spinal cord, and optic nerve. There are now
2.8 million people worldwide who have MS, and every five minutes,
someone, somewhere in the world is diagnosed with this disorder.
While there is no way to predict with any certainty how an
individual’s disease will progress, four basic MS disease courses
(also called types or phenotypes) have been defined: clinically
isolated syndrome, relapsing remitting, secondary progressive and
primary progressive. The most common affecting around 85 per cent
of everyone diagnosed with MS is relapsing remitting MS (RRMS). It
means that symptoms appear (a relapse), and then fade away, either
partially or completely (remitting).
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics is a biotechnology company
primarily focused on the discovery, research, and development of
innovative treatments for central nervous system (CNS) disorders.
We leverage our expertise in the fields of neuroscience, medicinal
chemistry, and translational medicine to develop new molecular
entities that target the pathophysiology underlying such diseases
with the goal of bringing life-changing therapies to patients.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the U.S. Securities and Exchange
Commission (SEC). Thus, actual results could be materially
different. The Company undertakes no obligation to update these
statements whether as a result of new information, future events or
otherwise, after the date of this release, except as required by
law.
Company ContactDr. Tiago Reis
MarquesChief Executive OfficerEmail: tiago@pasithea.com
Pasithea Therapeutics (NASDAQ:KTTAW)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024